RMC No. 2-2022 updates the list of VAT-exempt COVID-19 medicines under RA 11534, affecting pharmacies, hospitals, and suppliers. Businesses must adjust VAT treatment immediately.
Businesses must now ensure their VAT compliance reflects the latest list of COVID-19 medicines that are exempt from value-added tax under Republic Act No. 11534. The Department of Health has officially endorsed updates, affecting suppliers, hospitals, clinics, and pharmaceutical distributors. Immediate review of inventory and billing systems is critical to avoid misapplication of VAT.
What Changed
RMC No. 2-2022 publishes the full text of the DOH letter updating the list of COVID-19 drugs and vaccines that are VAT-exempt. Additions include anesthetics, analgesics (opioids), neuromuscular blockers, cardiac drugs, inhaled corticosteroids, and emergency use COVID-19 vaccines. Notably, monoclonal antibodies such as Casirivimab + Imdevimab and COVID-19 vaccines from Pfizer, Moderna, and Sinovac are specified, along with their formulations and vial sizes. The list clarifies that all salt forms of these drugs are covered for VAT exemption
RMC No. 2-2022 Publishes the ofโฆ
.
Who is Affected
Pharmacies, hospitals, clinics, suppliers, and distributors of these COVID-19 medicines are directly impacted. Accounting and tax departments must update their VAT ledgers, billing systems, and compliance manuals. Manufacturers and importers must ensure the correct VAT treatment is applied at the point of sale or distribution. This also affects invoicing for insurance claims or government procurement where VAT compliance is scrutinized.
Key Compliance Requirements and Deadlines
All covered drugs and vaccines are to be recognized as VAT-exempt upon issuance of this circular. Internal revenue officers and concerned businesses should immediately update their records to reflect the exemption. Specific product details, such as concentrations, vial sizes, and routes of administration, must match DOH endorsements for proper VAT treatment. Failure to reflect updates may result in misclassified sales and inaccurate VAT reporting
RMC No. 2-2022 Publishes the ofโฆ
.
Penalties for Non-Compliance
Incorrect VAT reporting or failure to apply exemptions to the newly listed medicines could result in penalties, interest, or administrative action by the BIR. Businesses must document adherence to the updated list to mitigate audit risks. Proper internal controls, including cross-verification with DOH-endorsed lists, are recommended.
Practical Steps for Businesses
1. Review the updated DOH-endorsed list published under RMC No. 2-2022 (pages 8โ16 of the circular). 2. Update your ERP, billing, and invoicing systems to mark these medicines as VAT-exempt. 3. Train accounting and pharmacy staff on the new VAT-exempt items. 4. Maintain a reference copy of RMC No. 2-2022 for audit and regulatory compliance purposes. 5. Coordinate with suppliers to ensure VAT-exempt treatment is reflected in invoices and delivery receipts. 6. Monitor future BIR or DOH communications for additional updates or clarifications.
By taking these steps, businesses can ensure full compliance with VAT regulations while facilitating access to critical COVID-19 medicines. Ablola, Saribong & Gueco provides comprehensive guidance to help your company update VAT treatment accurately and maintain audit-ready records. Visit MakatiLawFirm.com for professional support and practical compliance solutions.